The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Lebrikizumab Treatment in Adults with Asthma
Abstract
BACKGROUND: Many patients with asthma have uncontrolled disease despite treatment with inhaled glucocorticoids. One potential cause of the variability in response to treatment is heterogeneity in the role of interleukin-13 expression in the clinical asthma phenotype. We hypothesized that anti-interleukin-13 therapy would benefit patients with asthma who had a pretreatment profile consistent with interleukin-13 activity. METHODS: We conducted a randomized, double-blind, placebo-controlled study of lebrikizumab, a monoclonal antibody to interleukin-13, in 219 adults who had asthma that was inadequately controlled despite inhaled glucocorticoid therapy. The primary efficacy outcome was the relative change in prebronchodilator forced expiratory volume in 1 second (FEV(1)) from baseline to week 12. Among the secondary outcomes was the rate of asthma exacerbations through 24 weeks. Patient subgroups were prespecified according to baseline type 2 helper T-cell (Th2) status (assessed on the basis of total IgE level and blood eosinophil count) and serum periostin level. RESULTS: At baseline, patients had a mean FEV(1) that was 65% of the predicted value and were taking a mean dose of inhaled glucocorticoids of 580 μg per day; 80% were also taking a long-acting beta-agonist. At week 12, the mean increase in FEV(1) was 5.5 percentage points higher in the lebrikizumab group than in the placebo group (P = 0.02). Among patients in the high-periostin subgroup, the increase from baseline FEV(1) was 8.2 percentage points higher in the lebrikizumab group than in the placebo group (P = 0.03). Among patients in the low-periostin subgroup, the increase from baseline FEV(1) was 1.6 percentage points higher in the lebrikizumab group than in the placebo group (P = 0.61). Musculoskeletal side effects were more common with lebrikizumab than with placebo (13.2% vs. 5.4%, P = 0.045). CONCLUSIONS: Lebrikizumab treatment was associated with improved lung function. Patients with high pretreatment levels of serum periostin had greater improvement in lung function with lebrikizumab than did patients with low periostin levels. (Funded by Genentech; ClinicalTrials.gov number, NCT00930163 .).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Development and validation of a questionnaire to measure asthma control
Juniper, E. F., O′byrne, P. M., Guyatt, G. H., Ferrie, P. J., & King, D. R. (1999) · European Respiratory Journal · doi:10.1034/j.1399-3003.1999.14d29.x · Cited by 2,473
Identification of Asthma Phenotypes Using Cluster Analysis in the Severe Asthma Research Program
Moore, W. C., Meyers, D. A., Wenzel, S. E., Teague, W. G., Li, H., Li, X., D'Agostino, R., Castro, M., Curran-Everett, D., Fitzpatrick, A. M., et al. (2010) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200906-0896oc · Cited by 2,129
Cluster analysis and clinical asthma phenotypes
Haldar, P., Pavord, I. D., Shaw, D. E., Berry, M. A., Thomas, M., Brightling, C. E., Wardlaw, A. J., & Green, R. H. (2008) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200711-1754oc · Cited by 1,987
T-helper Type 2–driven Inflammation Defines Major Subphenotypes of Asthma
Woodruff, P. G., Modrek, B., Choy, D. F., Jia, G., Abbas, A. R., Ellwanger, A., Arron, J. R., Koth, L. L., & Fahy, J. V. (2009) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200903-0392oc · Cited by 1,803
Self-citationCan Guideline-defined Asthma Control Be Achieved?: The Gaining Optimal Asthma ControL Study
Bateman, E. D., Boushey, H. A., Bousquet, J., Busse, W. W., Clark, T. J. H., Pauwels, R. A., & Pedersen, S. E. (2004) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200401-033oc · Cited by 1,594
Statistics in Medicine — Reporting of Subgroup Analyses in Clinical Trials
Wang, R., Lagakos, S. W., Ware, J. H., Hunter, D. J., & Drazen, J. M. (2007) · New England Journal of Medicine · doi:10.1056/nejmsr077003 · Cited by 1,445
Asthma: defining of the persistent adult phenotypes
Wenzel, S. E. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69290-8 · Cited by 1,043
Endotyping asthma: new insights into key pathogenic mechanisms in a complex, heterogeneous disease
Anderson, G. P. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61452-x · Cited by 999
Glucocorticoid resistance in inflammatory diseases
Barnes, P. J., & Adcock, I. M. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60326-3 · Cited by 983
Juniper, E. F., Svensson, K., Mörk, A.-C., & Ståhl, E. (2005) · Respiratory Medicine · doi:10.1016/j.rmed.2004.10.008 · Cited by 929
Cited by
Items 101–115 of 115
Combination therapy: the future of management for idiopathic pulmonary fibrosis?
Wuyts, W. A., Antoniou, K. M., Borensztajn, K., Costabel, U., Cottin, V., Crestani, B., Grutters, J. C., Maher, T. M., Poletti, V., Richeldi, L., et al. (2014) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(14)70232-2 · Cited by 150
Type 2 immunity is protective in metabolic disease but exacerbates NAFLD collaboratively with TGF-β
Hart, K. M., Fabre, T., Sciurba, J. C., Gieseck, R. L., Borthwick, L. A., Vannella, K. M., Acciani, T. H., de Queiroz Prado, R., Thompson, R. W., White, S., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aal3694 · Cited by 143
Self-citationFrailty phenotypes and mortality after lung transplantation: a prospective cohort study
Singer, J. P., Diamond, J. M., Anderson, M. R., Katz, P. P., Covinsky, K., Oyster, M., Blue, T., Soong, A., Kalman, L., Shrestha, P., et al. (2018) · American Journal of Transplantation · doi:10.1111/ajt.14873 · Cited by 133
Del Giacco, S. R., Bakirtas, A., Bel, E., Custovic, A., Diamant, Z., Hamelmann, E., Heffler, E., Kalayci, Ö., Saglani, S., Sergejeva, S., et al. (2017) · Allergy · doi:10.1111/all.13072 · Cited by 130
“An interesting distinction of adult asthma phenotypes based on gene expression of periostin by airway epithelial cells includes the separation in Th2 high and Th2 low phenotypes (77), and the utility of this biomarker to predict therapeutic response to antibodies that block Th2 cytokines (78).”
BackgroundAdcock, I. M., & Mumby, S. (2016) · Handbook of experimental pharmacology · doi:10.1007/164_2016_98 · Cited by 131
The Complex Type 2 Endotype in Allergy and Asthma: From Laboratory to Bedside
Agache, I., Sugita, K., Morita, H., Akdis, M., & Akdis, C. A. (2015) · Current Allergy and Asthma Reports · doi:10.1007/s11882-015-0529-x · Cited by 86
Novel Biologicals for the Treatment of Allergic Diseases and Asthma
Tan, H.-T. T., Sugita, K., & Akdis, C. A. (2016) · Current Allergy and Asthma Reports · doi:10.1007/s11882-016-0650-5 · Cited by 68
Disaggregating asthma: big investigation versus big data
Belgrave, D., Henderson, J., Simpson, A., Buchan, I., Bishop, C., & Custovic, A. (2017) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2016.11.003 · Cited by 67
Asthma in the Precision Medicine Era: Biologics and Probiotics
Chiu, C.-J., & Huang, M.-T. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094528 · Cited by 60
Edwards, M. R., Saglani, S., Schwarze, J., Skevaki, C., Smith, J. A., Ainsworth, B., Almond, M., Andreakos, E., Belvisi, M. G., Chung, K. F., et al. (2017) · European Respiratory Journal · doi:10.1183/13993003.02448-2016 · Cited by 55
Kenyon, N. J., Bratt, J. M., Lee, J., Luo, J., Franzi, L. M., Zeki, A. A., & Lam, K. S. (2013) · PLoS ONE · doi:10.1371/journal.pone.0077730 · Cited by 53
Repetitive intradermal bleomycin injections evoke T-helper cell 2 cytokine-driven pulmonary fibrosis
Singh, B., Kasam, R. K., Sontake, V., Wynn, T. A., & Madala, S. K. (2017) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00184.2017 · Cited by 48
The origin and role of innate lymphoid cells in the lung
Lai, D.-M., Shu, Q., & Fan, J. (2016) · Military Medical Research · doi:10.1186/s40779-016-0093-2 · Cited by 45
Hong, C.-H., Lin, S.-H., Clausen, B. E., & Lee, C.-H. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1917479117 · Cited by 17
“In agreement, targeting IL-4R (31) or IL-13 (32) both result in clinical improvement of Th2-mediated diseases, including atopic dermatitis and allergic asthma.”
BackgroundRefractory asthma - beyond step 5, the role of new and emerging adjuvant therapies
Kane, B., Fowler, S. J., & Niven, R. (2015) · Chronic Respiratory Disease · doi:10.1177/1479972314562210 · Cited by 15
“As per the anti-IL-5 antibody mepolizumab, this agent only demonstrated clinical effectiveness when the population was stratified for their eosinophilic pattern of airway inflammation.(55) Pitrakinra reduced allergen-induced late asthmatic responses and the need for rescue medication with minimal side effects.”
Background
Metadata
- Authors
- Corren, J., Lemanske, R. F., Hanania, N. A., Korenblat, P. E., Parsey, M. V., Arron, J. R., Harris, J. M., Scheerens, H., Wu, L. C., Su, Z., Mosesova, S., Eisner, M. D., Bohen, S. P., & Matthews, J. G.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2011-09-22
- Volume
- 365
- Issue
- 12
- Pages
- 1088-1098
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2127482775
- Cited by
- 1,514
- References
- 26
- FWCI
- 94.38
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.